Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBM588 for Prevention of Recurrent C. difficile Infection
NCT01077245Phase 2Withdrawn
- Sponsor
- Osel Inc.
- Start
- Feb 2010
- Primary completion
- Nov 2013
- Modality
- Live Biotherapeutic Products
01
Overview
Phase 2, randomised, double-blind trial in Clostridium difficile infection (CDI) comparing MIYA-BM with Placebo (2 arms). Primary endpoint: Safety of MIYA-BM at 180 days. Planned start Feb 2010; status: withdrawn.
02
Drugs
MO-03
03
Conditions
Clostridium difficile infection (CDI)
Beyond the preview
Go deeper on NCT01077245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01077245.